Low-dose oral Minoxidil for Hair loss found to be Safe & Eff
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The major concern regarding the use of low-dose oral minoxidil (LDOM) in the treatment of hair loss is the potential risk of systemic adverse effects. A Study was conducted to describe the safety of LDOM for the treatment of hair loss in a large cohort of patients.

A retrospective multicenter study was conducted of patients treated with LDOM for at least 3 months as a treatment for any type of alopecia. A total of 1404 patients [943 women (67.2%) and 461 men (32.8%)] with a mean age of 43 years (range 8-86) were included.

Results:
--From them, the dose of LDOM was titrated in 1065 patients, allowing the analysis of 2469 different cases.

--The most frequent adverse effect was hypertrichosis (15.1%) which led to treatment withdrawal in 14 patients (0.5%). Systemic adverse effects included lightheadedness (1.7%), fluid retention (1.3%), tachycardia (0.9%), headache (0.4%), periorbital edema (0.3%) and insomnia (0.2%), leading to drug discontinuation in 29 patients (1.2%).

--No life-threatening adverse effects were observed.

LDOM has a good hair loss care safety profile in particular. Systemic adverse effects were rare and the therapy was stopped because of adverse effects in 1.7% of the patients.

Source: https://www.jaad.org/article/S0190-9622(21)00418-7/fulltext?rss=yes
Like
Comment
Share